Public Adverse Event Data Insights into the Safety of Pembrolizumab in Melanoma Patients

Immune checkpoint inhibition represents an important therapeutic option for advanced melanoma patients. Results from clinical studies have shown that treatment with the PD-1 inhibitors Pembrolizumab and Nivolumab provides improved response and survival rates. Moreover, combining Nivolumab with the C...

Descripción completa

Detalles Bibliográficos
Autores principales: Schaefer, Anne, Sachpekidis, Christos, Diella, Francesca, Doerks, Anja, Kratz, Anne-Sophie, Meisel, Christian, Jackson, David B., Soldatos, Theodoros G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226447/
https://www.ncbi.nlm.nih.gov/pubmed/32325840
http://dx.doi.org/10.3390/cancers12041008

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226447/
https://www.ncbi.nlm.nih.gov/pubmed/32325840
http://dx.doi.org/10.3390/cancers12041008

Ejemplares similares